Association Between Early Methadone Dose Titration and Treatment Discontinuation and Opioid Toxi

• The study analyzes whether providing an early methadone dose increase within treatment days 4–6 is associated with subsequent treatment discontinuation and opioid-related toxicity among people initiating methadone in outpatient settings.
• The question is framed against guidelines recommending faster titration for individuals who use fentanyl, specifically examining outpatient outcomes and the impact of an early dose uptitration.

Secondary—methadone-related versus non-methadone-related toxicity while on treatment.

Weighted Cox proportional hazards models assessed associations between early titration and outcomes.

• Design: Retrospective cohort with propensity-score weighting.
• Setting and population: Ontario residents initiating outpatient methadone between January 2017 and December 2022.
• Exposure definition: Early dose titration—receipt of a dose increase between days 4 and 6 of treatment (index date = date of first dose increase).
• Comparator: No early dose titration (index date assigned randomly to mirror the exposure distribution for analytic symmetry).
• Follow-up: Up to 181 days after index date for outcomes.
• Outcomes: Primary—methadone discontinuation and opioid toxicity (intention-to-treat).
• Analytic approach: Propensity-score modeling to estimate the likelihood of receiving early titration based on baseline demographics and clinical history (e.g., comorbidities, prior medications).

• Total incident methadone recipients: 13,560.
• Early titration: 61.4% (n = 8,322).
• Mean age: 36.5 years.
• Sex: roughly one-third female.
• The analysis relies on baseline variables used in the propensity model, with intended balance between exposed and unexposed groups.

The protective signal attenuated over time.

Non-methadone opioid–related toxicity predominated, with similar absolute rates in exposed vs unexposed groups (3.89 vs 4.06 per 100 person-years; wHR 1.00; 95% CI 0.70–1.44).

• Treatment discontinuation: Early dose titration was associated with a lower weighted hazard of discontinuation, especially in the first week after index date (wHR 0.55; 95% CI 0.51–0.60).
• Opioid toxicity overall: The weighted incidence of opioid toxicity was lower among those exposed to early titration compared with unexposed individuals (10.1 vs 12.3 per 100 person-years; wHR 0.82; 95% CI 0.69–0.97).
• Opioid toxicity while on treatment: No increased risk with early titration.
• Methadone-related toxicity while on treatment: Comparable between groups (2.02 vs 2.65 per 100 person-years; wHR 0.80; 95% CI 0.46–1.41).

• The principal limitation is potential residual confounding due to unmeasured factors such as and time-varying clinical characteristics and comprehensive drug-use history, which were not captured and could influence both titration likelihood and outcomes.
• As with observational designs, causality cannot be definitively established, though results are adjusted via propensity weighting and show a consistent pattern favoring early titration for retention and overall opioid toxicity risk.
• The study does not provide granular data on the exact dosing increments or the magnitude of dose increases beyond the designation of an “early titration.”

• In a population with substantial fentanyl exposure, early dose titration appears associated with improved retention in care and a lower hazard of opioid toxicity, driven largely by reductions in non-methadone opioid events.
• The safety signal does not indicate increased methadone-specific toxicity with early titration during treatment.
• Authors highlight logistical barriers to timely dose increases as a modifiable factor that may influence retention outcomes, suggesting system-level efforts to streamline dose adjustment could be beneficial.